Skip to Content

Month: October 2019

Joe Biden said in 1998 that Clinton impeachment could be seen as ‘partisan lynching’

Democratic presidential candidate Joe Biden on Tuesday denounced President Donald Trump’s comparison of the ongoing impeachment inquiry to a “lynching,” but in a 1998 interview, the then-senator from Delaware also invoked the term in reference to impeachment. “Impeachment is not ‘lynching,’ it is part of our Constitution,” the former vice president said in a tweet

Continue Reading

Renuncia el vicepresidente del Tribunal Electoral de Bolivia en medio de denuncias de fraude en elecciones

(CNN Español) — El vicepresidente del Tribunal Supremo Electoral de Bolivia, Antonio Costas, renunció a su cargo por lo que llamó “desacuerdos” con la medida de suspensión de publicación de conteo rápido de los votos de la elección presidencial por casi 24 horas. En carta dirigida al vicepresidente del Estado Plurinacional de Bolivia, Costas explica

Continue Reading

A wave of civil disobedience is bursting out all over the globe — Meanwhile in America

Fires burn on shut-down boulevards, protestors throw rocks and bottles, armor-clad security forces advance. A wave of civil disobedience is bursting out all over the globe. Fury over economic inequality, price hikes and corruption keeps blowing its lid in Ecuador, France, Chile and Lebanon. In Hong Kong and Catalonia, demonstrators demand political freedoms. In the

Continue Reading

Farmacéutica hace nuevo intento para lograr aprobación de la FDA para tratamiento del alzhéimer

(CNN) — En un cambio inesperado, el gigante farmacéutico Biogen dijo que buscará la aprobación de la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) para aducanumab, un tratamiento experimental contra la enfermedad de Alzheimer en sus etapas tempranas, anunciaron este martes Biogen y su socio japonés Eisai. MIRA: El nuevo

Continue Reading

Drugmaker reverses course, plans to seek FDA approval for Alzheimer’s treatment

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for aducanumab, an experimental treatment for early Alzheimer’s disease, Biogen and its Japanese partner Eisai announced on Tuesday. Phase 3 clinical studies of aducanumab were discontinued in March. The trials were halted because results of a futility analysis

Continue Reading